Industri

PFAS in Medical Devices: Material Applications, Regulat...

Per- and polyfluoroalkyl substances (PFAS), often referred to as “forever chemic...

Mecho Healthcare Shading Solutions

Mecho’s health care shading solutions encompass manual, motorized and automated ...

Memorial Healthcare System Elevates Stephen Demers and ...

Memorial Healthcare System has announced two leadership promotions, naming Felic...

Amberstone and Henlius agree to develop solid-tumour T-...

The preclinical T-cell engagers will be developed using Amberstone’s Tumor Micro...

FDA approves Lilly’s Onswik for type 2 diabetes in adults

This treatment is approved for use alongside diet and exercise to improve blood ...

Genialis and Inventia to enhance pancreatic cancer trea...

The companies will integrate the Genialis Supermodel with Inventia’s RASTRUM 3D ...

Basecamp Research secures $140m for AI-driven therapies

S32 led the oversubscribed financing round. Investors included Catalio Capital M...

Generic Remedy crosses 700+ franchise outlets across 9 ...

India’s emerging True MRP generic pharmacy network expands rapidly since its No...

Skanska Completes $27.3 Million Broward Health Emergenc...

The new $27.3 million, 18,000-square-foot Broward Health Sunrise ER will provide...

Boehringer and Envisagenics to develop precision cancer...

Under the agreement, Envisagenics is set to receive more than $1bn through poten...

BoomRay and Novartis Pharma sign $900m deal for radioli...

The agreement includes an upfront payment, as well as potential development, reg...

Treating hair loss as a health issue, not just a hairca...

Traya has treated hair loss as a health issue rather than simply a cosmetic con...

A missed opportunity for GS1 to explain why India’s bar...

A recent essay in Express Pharma by Mr. S. Swaminathan, CEO of GS1 India, extol...

ERS Genomics and Sai Life Sciences sign CRISPR/Cas9 lic...

ERS Genomics Limited (‘ERS’), the CRISPR licensing company, announced that it h...

SIRO Clintech reloaded 

Corporate history is replete with examples of the ‘third generation curse’, but...

EC approves Menarini and NewAmsterdam’s obicetrapib the...

The authorisation allows both treatments to be used for patients with primary hy...